Comparative Pharmacology
Head-to-head clinical analysis: Q GESIC versus VICOPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: Q GESIC versus VICOPROFEN.
Q-GESIC vs VICOPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Q-GESIC is a centrally acting non-opioid analgesic; its exact mechanism is unknown but may involve inhibition of cyclooxygenase (COX) and modulation of descending serotonergic and noradrenergic pathways.
Hydrocodone is a mu-opioid receptor agonist that activates G-protein coupled opioid receptors, leading to analgesia; ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
1-2 tablets (325-650 mg acetaminophen and 5-10 mg hydrocodone) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
1 tablet (hydrocodone 5 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours; clinical context: requires dosing every 4-6 hours for sustained analgesia.
Hydrocodone: 3.8-4.5 hours (immediate-release); clinical context: analgesic duration correlates with half-life, but may be prolonged in renal/hepatic impairment. Ibuprofen: 2-4 hours (immediate-release); clinical context: anti-inflammatory effect may outlast plasma half-life due to tissue distribution.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; <5% metabolized via CYP enzymes.
Hydrocodone: primarily renal (26% as unchanged drug and metabolites, including norhydrocodone, hydromorphone, and conjugates); less than 5% fecal. Ibuprofen: renal (50-60% as unchanged drug and metabolites, mainly conjugated with glucuronic acid; <10% unchanged); biliary/fecal (minor).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination